ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Masons Give $65 Million to Univ. of Minnesota Cancer Center.

April 25, 2008

In Brief: ACS Asks Removal Of Dollar Authorization Levels; FDA May Overrule Advisors On Estramustine

November 23, 1979

In Brief: Leaks From Cooperative Group Site Visits Vex CCIRC; Tumor Cell Cloning Workshop Set

August 11, 1978

NCI Program: reports Urges Expansion of Surveillance Program To Better Explain Trends

April 30, 1999

President, Congress, Cancer Letter Take Off

August 22, 1986

Reed To Leave NCI Next Year; Allegra Moves To Extramural Side; Ozer Heads Okla. Center.

July 21, 2000